MILAN, Italy, April 22, 2008 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies, announced today that the European Medicines Evaluation Agency (EMEA) confirmed that a marketing application for EUR-1008 (Zentase) is eligible for Community (Centralized) Marketing Authorization submission in the European Union (EU). Eligibility was granted under Article 3(2)b of regulation EC No. 726/2004, which relates to products that offer a significant technological innovation.
